nach oben

Erschienen in:

01.03.2016 | Original Article

Evaluation of chemotherapeutic sequelae and quality of life in survivors of malignant sacrococcygeal teratoma

verfasst von: Marijke E. B. Kremer, Joep P. M. Derikx, Leontien C. M. Kremer, Robertine van Baren, Hugo A. Heij, Marc H. W. A. Wijnen, René M. H. Wijnen, David C. van der Zee, L. W. Ernest van Heurn

Erschienen in: Pediatric Surgery International | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The impact of chemotherapeutic sequelae on long-term quality of life (QoL) for survivors of malignant sacrococcygeal teratoma (SCT) is unknown. The incidence of chemotherapeutic toxicity in patients treated for malignant SCT and possible effects on the QoL were analyzed.

Methods

Retrospective chart review of patients ≥18 years treated for SCT in the Netherlands was performed. Present QoL was evaluated using the SF-36 questionnaire. The results of survivors of malignant SCT were compared to those of patients treated for benign SCT.

Results

Fifty-one of 76 traceable patients consented to participate. The results of 47 (92.2 %), 9 men and 38 women (median age 25.4 years, range 18.3–41.2), were analyzed. Eleven had been treated for malignancy; 63.6 % suffered from at least one chemotherapeutic sequel with hearing loss as the most common one. Results for both groups were similar on all but one SF-36 subcategory; those treated for malignant tumor scored significantly lower on the subcategory physical functioning (p = 0.02).

Conclusion

Despite the high incidence of chemotherapeutic sequelae among survivors of malignant SCT, their QoL does not differ from that of those treated for benign SCT. Even though their physical functioning is restricted, daily activities and psychosocial functioning of survivors of malignant SCT are not restricted.

Barksdale EM Jr, Obokhare I (2009) Teratomas in infants and children. Curr Opin Pediatr 21:344–349CrossRefPubMed

Pauniaho SL, Heikinheimo O, Vettenranta K, Salonen J, Stefanovic V, Ritvanen A, Rintala R, Heikinheimo M (2013) High prevalence of sacrococcygeal teratoma in Finland—a nationwide population-based study. Acta Paediatr 102:e251–e256CrossRefPubMed

Schropp KP, Lobe TE, Rao B, Mutabagani K, Kay GA, Gilchrist BF, Philippe PG, Boles ET Jr (1992) Sacrococcygeal teratoma: the experience of four decades. J Pediatr Surg 27:1075–1078CrossRefPubMed

Altman RP, Randolph JG, Lilly JR (1974) Sacrococcygeal teratoma: American Academy of Pediatrics Surgical Section Survey-1973. J Pediatr Surg 9:389–398CrossRefPubMed

Derikx JP, De Backer A, van de Schoot L, Aronson DC, de Langen ZJ, van den Hoonaard TL, Bax NM, van der Staak F, van Heurn LW (2006) Factors associated with recurrence and metastasis in sacrococcygeal teratoma. Br J Surg 93:1543–1548CrossRefPubMed

Rescorla FJ (2012) Pediatric germ cell tumors. Semin Pediatric Surg 21:51–60CrossRef

Yoshida M, Matsuoka K, Nakazawa A, Yoshida M, Inoue T, Kishimoto H, Nakayama M, Takaba E, Hamazaki M, Yokoyama S, Horie H, Tanaka M, Gomi K, Ohama Y, Kigasawa H, Kitano Y, Uchida H, Kanamori Y, Iwanaka T, Tanaka Y (2013) Sacrococcygeal yolk sac tumor developing after teratoma: a clinicopathological study of pediatric sacrococcygeal germ cell tumors and a proposal of the pathogenesis of sacrococcygeal yolk sac tumors. J Pediatr Surg 48:776–781CrossRefPubMed

Rescorla FJ, Sawin RS, Coran AG, Dillon PW, Azizkhan RG (1998) Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Childrens Cancer Group. J Pediatr Surg 33:171–176CrossRefPubMed

Engelskirchen R, Holschneider AM, Rhein R, Hecker WC, Hopner F (1987) Sacral teratomas in childhood. An analysis of long-term results in 87 children. Z Kinderchir 42:358–361PubMed

10.

Gobel U, Calaminus G, Blohm M, Booss D, Felberbauer F, Hofmann U, Holschneider AM, Willnow U, Harms D (1997) Extracranial non-testicular teratoma in childhood and adolescence: introduction of a risk score for stratification of therapy. Klin Padiatr 209:228–234CrossRefPubMed

11.

Calaminus G, Schneider DT, Bokkerink JP, Gadner H, Harms D, Willers R, Gobel U (2003) Prognostic value of tumor size, metastases, extension into bone, and increased tumor marker in children with malignant sacrococcygeal germ cell tumors: a prospective evaluation of 71 patients treated in the German cooperative protocols Maligne Keimzelltumoren (MAKEI) 83/86 and MAKEI 89. J Clin Oncol 21:781–786CrossRefPubMed

12.

Gobel U, Schneider DT, Calaminus G, Jurgens H, Spaar HJ, Sternschulte W, Waag K, Harms D (2001) Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. J Clin Oncol 19:1943–1950PubMed

13.

De Corti F, Sarnacki S, Patte C, Mosseri V, Baranzelli MC, Martelli H, Conter C, Frappaz D, Orbach D (2012) Prognosis of malignant sacrococcygeal germ cell tumours according to their natural history and surgical management. Surg Oncol 21:e31–e37CrossRefPubMed

14.

Mann JR, Raafat F, Robinson K, Imeson J, Gornall P, Phillips M, Sokal M, Gray E, McKeever P, Oakhill A (1998) UKCCSG’s germ cell tumour (GCT) studies: improving outcome for children with malignant extracranial non-gonadal tumours–carboplatin, etoposide, and bleomycin are effective and less toxic than previous regimens. United Kingdom Children’s Cancer Study Group. Med Pediatr Oncol 30:217–227CrossRefPubMed

15.

Hale GA, Marina NM, Jones-Wallace D, Greenwald CA, Jenkins JJ, Rao BN, Luo X, Hudson MM (1999) Late effects of treatment for germ cell tumors during childhood and adolescence. J Pediatr Hematol Oncol 21:115–122CrossRefPubMed

16.

Gobel U, Calaminus G, Teske C, Bamberg M, Bokkerink JP, Haas RJ, Holschneider AM, Janka-Schaub G, Jurgens H, Mittler U et al (1993) BEP/VIP in children and adolescents with malignant non-testicular germ cell tumors. A comparison of the results of treatment of therapy studies MAKEI 83/86 and 89P/89. Klin Padiatr 205:231–240CrossRefPubMed

17.

Derikx JP, De Backer A, van de Schoot L, Aronson DC, de Langen ZJ, van den Hoonaard TL, Bax NM, van der Staak F, van Heurn LW (2007) Long-term functional sequelae of sacrococcygeal teratoma: a national study in The Netherlands. J Pediatr Surg 42:1122–1126CrossRefPubMed

18.

Dirix M, van Becelaere T, Berkenbosch L, van Baren R, Wijnen RM, Wijnen MH, van der Zee DC, Heij HA, Derikx JP, van Heurn LW (2015) Malignant transformation in sacrococcygeal teratoma and in presacral teratoma associated with Currarino syndrome: a comparative study. J Pediatr Surg 50:462–464CrossRefPubMed

19.

Currarino G, Coln D, Votteler T (1981) Triad of anorectal, sacral, and presacral anomalies. AJR Am J Roentgenol 137:395–398CrossRefPubMed

20.

Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E (1998) Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 51:1055–1068CrossRefPubMed

21.

Ware JE, Kosinski M (2001) Interpreting SF-36 summary health measures: a response. Qual Life Res 10:405–413 (discussion 415–420) CrossRefPubMed

22.

Rescorla F, Billmire D, Stolar C, Vinocur C, Colombani P, Cullen J, Giller R, Cushing B, Lauer S, Davis M, Hawkins E, Shuster J, Krailo M (2001) The effect of cisplatin dose and surgical resection in children with malignant germ cell tumors at the sacrococcygeal region: a pediatric intergroup trial (POG 9049/CCG 8882). J Pediatr Surg 36:12–17CrossRefPubMed

23.

Gobel U, Schneider DT, Calaminus G, Haas RJ, Schmidt P, Harms D (2000) Germ-cell tumors in childhood and adolescence. GPOH MAKEI and the MAHO study groups. Ann Oncol 11:263–271CrossRefPubMed

24.

Schacht J, Talaska AE, Rybak LP (2012) Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention. Anat Rec 295:1837–1850CrossRef

25.

SKION LATER Work group (2010) Richtlijn follow-up na kinderkanker meer dan 5 jaar na diagnose. Den Haag/Amsterdam. https://www.skion.nl/workspace/uploads/richtlijn_follow-up_na_kinderkanker_deel_2_achtergrond__2.pdf

Titel: Evaluation of chemotherapeutic sequelae and quality of life in survivors of malignant sacrococcygeal teratoma
verfasst von: Marijke E. B. Kremer
Joep P. M. Derikx
Leontien C. M. Kremer
Robertine van Baren
Hugo A. Heij
Marc H. W. A. Wijnen
René M. H. Wijnen
David C. van der Zee
L. W. Ernest van Heurn
Publikationsdatum: 01.03.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Surgery International / Ausgabe 3/2016
Print ISSN: 0179-0358
Elektronische ISSN: 1437-9813
DOI: https://doi.org/10.1007/s00383-015-3842-5

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Evaluation of chemotherapeutic sequelae and quality of life in survivors of malignant sacrococcygeal teratoma